Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

EMIS has fallen too far, says house broker Numis Securities

CEO Andy Thorburn is focused for now on improving underlying operating procedures and performance, including a focus on the replacement GP systems contract for England, now perhaps 15-18 months away
Doctor's surgery
The service issues with NHS Digital resulted in a provision of £11mln in the 2017 results

Numis Securities has turned bullish on EMIS Group PLC (LON:EMIS) now the healthcare software firm's shares have fallen a fifth this year.

The software firm's nominated adviser admitted that today's full-year results were largely as trailed in January's trading statement, although as a consequence of slightly higher-than-expected guidance on costs Numis has trimmed its 2018 earnings per share forecasts by 2%.

READ: EMIS Group shares tumble 15% as it is hit by contract delays

The shares are now “too cheap”, although Numis concedes there is still much to do to reinvigorate growth.

The house broker's recommendation has moved to 'buy' from 'hold', although the price target has been slashed to 880p from 1,000p, reflecting the dismal share price performance in 2018.

The shares currently trade at 792p, up 10% on the day.

“The three key areas of focus for management for now are:

  1. Preparation for the key England GP's system replacement contract, which now looks likely during 2019 (we look for buyer focus to be on enabling new models of care, reducing overall NHS cost and improving service, rather than price, but perceived risk will remain);
  2. An upgrade to the group's core EMIS Web clinical management system, modernising it and making it more flexible;
  3. Resolution of the service level issues, working collaboratively with the customer,” Numis stated.

In the background management is working on detailed plans for growth, EMIS's Nomad revealed.

“While we see some risk of investor impatience for growth plans, we think that Andy Thorburn's approach is entirely appropriate and will help to build investor confidence in due course,” it concluded.

View full EMIS profile View Profile

EMIS Group Timeline

Related Articles

laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use